Skip to main content

Table 2 Tumour response

From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Response Category, n (%)

Eribulin/S-1 (n = 30)

Objective Response Rate; 95%CI

10 (33.3); 17.3–52.8

Complete Response

1 (3.3)

Partial Response

9 (30)

Stable Disease

12 (40)

Progressive Disease

7 (23.3)

Clinical Benefit Rate; 95%CI

13 (43.3); 25.5–62.6

Disease Control Rate; 95%CI

22 (73.3); 54.1–87.7

  1. The ORR was 33.3% (95% CI: 17.3 to 52.8), the DCR was 73.3% (n = 22; 95% CI: 54.1 to 87.7), and the CBR was 43.3% (n = 13; 95% CI: 25.5–62.6)
  2. In this study, ORR was evaluated only among patients who had measurable baseline disease according to the Response Evaluation Criteria in Solid Tumours, version 1.1
  3. Abbreviations: ORR Overall response, CBR Clinical benefit rate: CR + PR + SD (> 6 months); DCR Disease control rate: CR + PR + SD
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us